Latest KDNY reports update at 2023-08-07: 2023-Q22023-Q12022-Q4
Chinook Therapeutics logo
Chinook Therapeutics KDNY
$ 40.39 0.0%

Chinook Therapeutics Financial Statements 2011-2024 | KDNY

Annual Financial Statements Chinook Therapeutics

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.39 B 744 M 209 M - - - - - - - - -

Shares

64.4 M 45.6 M 13.2 M - - - - - - - - -

Historical Prices

21.6 16.3 15.9 5.9 13.2 37.5 57 141 - - - -

Net Income

-188 M -103 M -81.6 M -82.4 M - - - - - - - -

Revenue

6.13 M 51.6 M 827 K 17.3 M - - - - - - - -

Cost of Revenue

- - - - - - - - - - - -

Gross Profit

- - - 17.3 M - - - - - - - -

Operating Income

-185 M -99 M -56.2 M -20 M -101 M -106 M -71.9 M -13.6 M -19.1 M -14.5 M - -

Interest Expense

- - - 299 K -64 K -218 K -40 K -161 K 2.38 M 1.37 M - -

EBITDA

-182 M -95.9 M -55.1 M -89.9 M - - - - - - - -

Operating Expenses

- - - 107 M - - - - - - - -

General and Administrative Expenses

36.3 M 31.9 M 19.1 M 34.8 M - - - - - - - -

All numbers in USD currency

Quarterly Income Statement Chinook Therapeutics

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

71.6 M 70.7 M 65.5 M 67.8 M 62 M 58.3 M 54.8 M 44.7 M 43.9 M 42.3 M 42.3 M 4.46 M 4.47 M 4.46 M 4.5 M 16 M 80 M 79.7 M 79.6 M 79.1 M 78.8 M 77.9 M 77.7 M 75.2 M 71.1 M 68.2 M 67.9 M 65.1 M 64.4 M 63.8 M 63.6 M 62.3 M 52.7 M 416 K 362 K 329 K 295 K 295 K - - - - - - - - - - - -

Net Income

-66.9 M -60.2 M - -56 M -37.6 M -31.7 M - -30.7 M -42.6 M -37.2 M - -18.8 M -7.74 M -5.15 M -19.4 M -21 M -18.6 M -23.4 M -26.3 M -23.1 M -24.4 M -21.5 M -26.1 M -24.5 M -19.4 M -21.8 M -29.6 M -35.1 M 2.3 M -28.8 M 3.1 M 567 K -26.3 M -16.6 M -920 K -4.68 M -3.63 M -7.78 M - - - - - - - - - - - -

Revenue

1.01 M 1.83 M - 2.5 M 418 K 2.7 M - 4 K 34 K 351 K - 3.79 M 5.57 M 14 M 3.63 M 4.8 M 4.89 M 3.94 M 2.76 M 3.06 M 2.64 M 6.63 M 3.76 M 3.79 M 5.92 M 3.77 M 3.88 M 3.79 M 39 M 4.03 M 34.4 M 19.1 M 9.88 M 9.57 M 9.89 M 2.49 M 985 K 25 K - - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-72.6 M -61.4 M - -57.7 M -36.7 M -30.8 M - -31 M -43.3 M -37.1 M - -10.5 M -7.75 M -4.09 M - -24.5 M -20.1 M -24.9 M - -24.9 M -25.8 M -22.7 M - -29.3 M -23.9 M -25.2 M - -23.9 M 3.26 M -26 M - 425 K -9.53 M -7.28 M - -5.35 M -6.55 M -6.09 M - - - - - - - - - - - -

Interest Expense

- - - 1.69 M 767 K -95 K - -69 K -39 K -67 K - 20 K -4 K 119 K - -32 K -3 K -19 K - 21 K -20 K -16 K - -129 K -64 K -4 K - -1 K -9 K -22 K - 3 K 7 K 8 K - 2.38 M 996 K 1.35 M - - - - - - - - - - - -

EBITDA

-71.1 M -60.5 M - -56.9 M -35.9 M -29.9 M - -30.2 M -42.5 M -36.4 M - -9.67 M -6.95 M -3.1 M - -23.4 M -19 M -23.8 M - -23.8 M -23.6 M -21.6 M - -26.7 M -23.1 M -24.4 M - -23.5 M 3.64 M -25.7 M - 587 K -9.41 M -7.19 M - -5.28 M -6.5 M -6.04 M - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - 37.5 M - 18.7 M 22.6 M 4.09 M - 29.3 M 25 M 28.9 M - 28 M 28.4 M 29.3 M - 33.1 M 29.8 M 29 M - 27.7 M 35.7 M 30.1 M - 18.7 M 19.4 M 16.9 M - 7.84 M 7.54 M 6.11 M - - - - - - - - - - - -

General and Administrative Expenses

13.1 M 11.4 M - 10 M 8.64 M 7.87 M - 6.85 M 7.77 M 9.54 M - 2.9 M 3.88 M 1.27 M - 8.6 M 7.83 M 8.22 M - 9.15 M 8.83 M 9.04 M - 8.46 M 8.24 M 8.28 M - 8.56 M 8.7 M 9 M - 6.91 M 5.88 M 6.21 M - 1.98 M 2.13 M 1.38 M - - - - - - - - - - - -

All numbers in USD currency